Top pharmaceutical companies by capex growth in 2022

Atea Pharmaceuticals had the highest capex growth among pharma and biotech companies worldwide during the 2022 period, with a growth rate of over 48,000 percent. Capital expenditures are defined as funds used by a company to acquire or upgrade physical assets, such as property, industrial buildings, or equipment. U.S. pharmaceutical and biotech industry Several of the pharmaceutical and biotech companies with high capex growth rates are based in the United States, for example, Atea Pharmaceuticals, Invivyd, and Pyxis Oncology. In 2022, the country accounted for over 40 percent of the global pharmaceutical market. China, which has a much larger population than the United States, had a roughly eight percent market share. In the same year, the United States spent over 600 billion U.S. dollars on medicine. This was more than double the amount spent back in 2009. The largest American pharmaceutical company based on revenue was Pfizer (according to the FT Global 500). The multinational biopharmaceutical company is headquartered in New York City and annually generates more than 100 billion U.S. dollars’ worth of annual revenue, as of 2022.

在2022年间，Atea制药公司在全球医药和生物技术公司中资本支出增长率最高，增长率超过48,000%。资本支出定义为公司用于购置或升级实物资产的资金，例如房产、工业建筑或设备。美国医药和生物技术行业，其中数家资本支出增长率较高的医药和生物技术公司位于美国，例如Atea制药公司、Invivyd和Pyxis肿瘤学。2022年，该国占全球医药市场超过40%的份额。中国，其人口数量远超美国，市场份额约为8%。同年，美国在药品上的支出超过6,000亿美元，是2009年的两倍以上。就收入而言，美国最大的制药公司为辉瑞公司（根据《FT全球500强》），这家跨国生物制药公司总部位于纽约市，截至2022年，其年度收入超过1,000亿美元。